

5 December 2017

## suPAR Pub Med Publications and Links

- **listed by publication year 2009-17**



### 2017

[Removal of focal segmental glomerulosclerosis \(FSGS\) factor suPAR using CytoSorb.](#)

Schenk H, Müller-Deile J, Schmitt R, Bräsen JH, Haller H, Schiffer M. J Clin Apher. 2017 Dec.

[Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation.](#)

Koh AS, Velmurugan B, Gao F, Tan RS, Wong JI, Teo LLY, Keng BMH, Chua SJM, Yuan JM, Koh WP, Cheung C. BMC Geriatr. 2017 Nov 28

[Sepsis biomarkers reprofiling to predict stroke-associated infections.](#)

Bustamante A, García-Berrocso T, Penalba A, Giralt D, Simats A, Muchada M, Zapata E, Rubiera M, Montaner J. J Neuroimmunol. 2017 Nov 15

[Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.](#)

Schaefer F, Trachtman H, Wühl E, Kirchner M, Hayek SS, Anarat A, Duzova A, Mir S, Paripovic D, Yilmaz A, Lugani F, Arbeiter K, Litwin M, Oh J, Matteucci MC, Gellermann J, Wygoda S, Jankauskiene A, Klaus G, Dusek J, Testa S, Zurowska A, Caldas Afonso A, Tracy M, Wei C, Sever S, Smoyer W, Reiser J; ESCAPE Trial Consortium and the 4C Study Group. JAMA Pediatr. 2017 Nov 6

[Could soluble urokinase plasminogen receptor \(suPAR\) be used as a diagnostic biomarker for ventilator-associated pneumonia?](#)

Sunnecioglu A, Sunnecioglu M, Adiyaman F, Binici I, Soyoral L. Clin Respir J. 2017 Nov

[Novel biomarkers for sepsis: A narrative review.](#)

Larsen FF, Petersen JA. Eur J Intern Med. 2017 Nov

[Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction.](#)

Fujisaka T, Fujita SI, Maeda D, Shibata K, Takahashi H, Morita H, Takeda Y, Ito T, Sohmiya K, Hoshiga M, Ishizaka N. Heart Vessels. 2017 Nov

[Prognostic and diagnostic potential of suPAR levels in pleural effusion.](#)

Matzkies LM, Raggam RB, Flick H, Rabensteiner J, Feierl G, Hoenigl M, Prattes J. J Infect. 2017 Nov

[Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.](#)

Kaminski TW, Pawlak K, Karbowska M, Mysliwiec M, Grzegorzewski W, Kuna J, Pawlak D. Int Urol Nephrol. 2017 Oct 22. [Epub]

[Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection.](#)

Kirkegaard-Klitbo DM, Langkilde A, Mejer N, Andersen O, Eugen-Olsen J, Benfield T. J Infect Dis. 2017 Oct 17 [Epub]

[Soluble urokinase-type plasminogen activator receptor \(suPAR\) and interleukin-6 levels in hyperemesis gravidarum.](#)

Desdicioglu R, Yildirim M, Kocaoglu G, Demir Cendek B, Avcioglu G, Tas EE, Sengul O, Erel O, Yavuz AF. J Chin Med Assoc. 2017 Oct 9 [Epub]

[How biomarkers reflect the prognosis and treatment of necrotising soft tissue infections and the effects of hyperbaric oxygen therapy: the protocol of the prospective cohort PROTREAT study conducted at a tertiary hospital in Copenhagen, Denmark.](#)

Polzik P, Johansson PI, Hyldegaard O. BMJ Open. 2017 Oct 5

[A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure.](#)

Lichtenauer M, Jirak P, Wernly B, Paar V, Rohm I, Jung C, Schernthaner C, Kraus J, Motloch LJ, Yilmaz A, Hoppe UC, Christian Schulze P, Kretzschmar D, Pistulli R. Eur J Intern Med. 2017 Oct

[Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation.](#)

Ichihara N, Miyamura M, Maeda D, Fujisaka T, Fujita SI, Morita H, Takeda Y, Ito T, Sohmiya K, Hoshiga M, Ishizaka N. J Arrhythm. 2017 Oct

[The relationship between levels of plasma-soluble urokinase plasminogen activator receptor \(suPAR\) and presence of migraine attack and aura.](#)

Yilmaz N, Yilmaz M, Sirin B, Yilmaztekin S, Kutlu G. J Recept Signal Transduct Res. 2017 Oct

[Nephrotic syndrome in infants and children: pathophysiology and management.](#)

Downie ML, Gallibois C, Parekh RS, Noone DG. Paediatr Int Child Health. 2017 Sep 15

[Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.](#)

Samman Tahhan A, Hayek SS, Sandesara P, Hajjari J, Hammadah M, O'Neal WT, Kelli HM, Alkhoder A, Ghasemzadeh N, Ko YA, Aida H, Gafeer MM, Abdelhadi N, Mohammed KH, Patel K, Arya S, Reiser J, Vaccarino V, Sperling L, Quyyumi A. *Atherosclerosis*. 2017 Sep

[Peripheral arterial disease outcomes and association with suPAR: A bridge to myeloid precursors or mast cells or both?](#)

Hoebaus C, Yussuf SM, Valent P, Scherthaner GH. *Atherosclerosis*. 2017 Sep

[Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.](#)

Kim EY, Roshanravan H, Dryer SE. *Biochim Biophys Acta*. 2017 Sep

[Multibiomarker analysis in patients with acute myocardial infarction.](#)

Scherthaner C, Lichtenauer M, Wernly B, Paar V, Pistulli R, Rohm I, Jung C, Figulla HR, Yilmaz A, Cadamuro J, Haschke-Becher E, Pernow J, Schulze PC, Hoppe UC, Kretzschmar D. *Eur J Clin Invest*. 2017 Sep

[High pneumococcal DNA load, procalcitonin and suPAR levels correlate to severe disease development in patients with pneumococcal pneumonia.](#)

Loonen AJM, Kesarsing C, Kusters R, Hilbink M, Wever PC, van den Brule AJC. *Eur J Clin Microbiol Infect Dis*. 2017 Sep

[SuPAR and FSGS: is the jury still out?](#)

Gallon L, Quaggin SE. *Nat Rev Nephrol*. 2017 Sep

[Experimental concerns regarding suPAR-related proteinuria.](#)

Mesnard L, Luque Y, Rondeau E. *Nat Rev Nephrol*. 2017 Sep

[Chronic kidney disease: Role of suPAR in APOL1-associated kidney disease.](#)

Carney EF. *Nat Rev Nephrol*. 2017 Sep

[Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and  \$\beta\$ 1 Integrin in Patients with Hodgkin's Lymphoma.](#)

Kouhpayeh S, Andalib A, Gharagozloo M, Sanei MH, Esmail N, Maracy MR. *Adv Biomed Res*. 2017 Aug 28

[A tripartite complex of suPAR, APOL1 risk variants and  \$\alpha\$ <sub>v</sub> \$\beta\$ <sub>3</sub> integrin on podocytes mediates chronic kidney disease.](#)

Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J. *Nat Med*. 2017 Aug

[Inflammation and post-operative recovery in patients undergoing total knee arthroplasty-secondary analysis of a randomized controlled trial.](#)

Langkilde A, Jakobsen TL, Bandholm TQ, Eugen-Olsen J, Blauenfeldt T, Petersen J, Andersen O. *Osteoarthritis Cartilage*. 2017 Aug.

[suPAR and chronic kidney disease-a podocyte story.](#)

Zeier M, Reiser J. *Pflugers Arch*. 2017 Aug

[Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.](#)

Mossanen JC, Pracht J, Jansen TU, Buendgens L, Stoppe C, Goetzenich A, Struck J, Autschbach R, Marx G, Tacke F. Int J Mol Sci. 2017 Jul 31

[Effect of a physical activity intervention on suPAR levels: A randomized controlled trial.](#)

Rohde C, Polcwiartek C, Andersen E, Vang T, Nielsen J. J Sci Med Sport. 2017 Jul 4

[Extrarenal determinants of kidney filter function.](#)

Hahm E, Peev V, Reiser J. Cell Tissue Res. 2017 Ju

[Serum levels of soluble urokinase plasminogen activator receptor \(suPAR\) as a marker of tuberculosis treatment efficacy.](#)

Indumati V, Vijay V, Krishnaswamy D, Rajeshwari V, Ramesh A, Shantala D, Shilpa A. Indian J Tuberc. 2017 Jul

[SCUBE1: a promising biomarker in renal cell cancer.](#)

Karagüzel E, Mentеше A, Kazaz İO, Demir S, Örem A, Okatan AE, Altay DU, Yaman SÖ. Int Braz J Urol. 2017 Jul-Aug.

[Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer.](#)

Rasmussen LJH, Schultz M, Gaardsting A, Ladelund S, Garred P, Iversen K, Eugen-Olsen J, Helms M, David KP, Kjaer A, Lebech AM, Kronborg G. Int J Cancer. 2017 Jul 1

[Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.](#)

Guo H, Zhou LX, Ma H, Liu B, Cheng J, Ma YY, Zhao L. Oncol Lett. 2017 Jul

[IFN- \$\gamma\$ , CXCL16, uPAR: potential biomarkers for systemic lupus erythematosus.](#)

Wen S, He F, Zhu X, Yuan S, Liu H, Sun L. Clin Exp Rheumatol. 2017 Jun 16. [Epub ahead of print]

[Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.](#)

von Scholten BJ, Persson F, Rosenlund S, Eugen-Olsen J, Pielak T, Faber J, Hansen TW, Rossing P. Diabetes Obes Metab. 2017 Jun

[How inflammation underlies physical and organ function in acutely admitted older medical patients.](#)

Klausen HH, Bodilsen AC, Petersen J, Bandholm T, Haupt T, Sivertsen DM, Andersen O. Mech Ageing Dev. 2017 Jun;164:67-75.

[Cleavage of the urokinase receptor \(uPAR\) on oral cancer cells: regulation by transforming growth factor -  \$\beta\$ 1 \(TGF- \$\beta\$ 1\) and potential effects on migration and invasion.](#)

Magnussen SN, Hadler-Olsen E, Costea DE, Berg E, Jacobsen CC, Mortensen B, Salo T, Martinez-Zubiaurre I, Winberg JO, Uhlin-Hansen L, Svineng G. BMC Cancer. 2017 May 19

[Prognostic Role of Circulating Soluble uPAR in Various Cancers: a Systematic Review and Meta-Analysis.](#)

Liu KL, Fan JH, Wu J. Clin Lab. 2017 May 1

[Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.](#)

Onatsu J, Taina M, Mustonen P, Hedman M, Muuronen A, Arponen O, Korhonen M, Jäkälä P, Vanninen R, Pulkki K. *In Vivo*. 2017 May-Jun;31(3):381-386.

[Kidney disease in Puumala hantavirus infection.](#)

Mustonen J, Outinen T, Laine O, Pörsti I, Vaheri A, Mäkelä S. *Infect Dis (Lond)*. 2017 May;49(5):321-332.

[Glomerular disease: A suPAR kidney connection found in the bone marrow.](#)

Gallon L, Quaggin SE. *Nat Rev Nephrol*. 2017 May;13(5):263-264.

[A high-protein diet during hospitalization is associated with an accelerated decrease in soluble urokinase plasminogen activator receptor levels in acutely ill elderly medical patients with SIRS.](#)

Tavenier J, Haupt TH, Andersen AL, Buhl SF, Langkilde A, Andersen JR, Jensen JB, Pedersen MM, Petersen J, Andersen O. *Nutr Res*. 2017 May;41:56-64.

[Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Is Not Associated with Neurological Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage.](#)

Kiiski H, Jalkanen V, Ala-Peijari M, Hämäläinen M, Moilanen E, Peltola J, Tenhunen J. *Front Neurol*. 2017 Apr 18;8:144.

[Effects of Acute Exercise on Circulating Soluble Form of the Urokinase Receptor in Patients With Major Depressive Disorder.](#)

Gustafsson A, Ventorp F, Wisén AG, Ohlsson L, Ljunggren L, Westrin Å. *Biomark Insights*. 2017 Apr 12;12:1177271917704193.

[Unwinding focal segmental glomerulosclerosis.](#)

Peev V, Hahm E, Reiser J. 2017 Apr 12

[Impact of lifestyle intervention for obese women during pregnancy on maternal metabolic and inflammatory markers.](#)

Renault KM, Carlsen EM, Hædersdal S, Nilas L, Secher NJ, Eugen-Olsen J, Cortes D, Olsen SF, Halldorsson TI, Nørgaard K. *Int J Obes (Lond)*. 2017 Apr;41(4):598-605.

[Prognostic Outcomes in Patients With Heart Failure: A New SuPAR Biomarker for Risk Prediction?](#)

Pemberton C. *JACC Heart Fail*. 2017 Apr;5(4):278-279.

[Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.](#)

Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, Mörtl D, Berger R, Goliash G, Wojta J, Hülsmann M, Niessner A. *JACC Heart Fail*. 2017 Apr;5(4):268-277.

[Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.](#)

Xiao Y, Luo H, Zhou B, Dai X, Huang J, Duan L, You Y, Zhang W, Zhao H, Xie Y, Zhou Y, Ning W, Li T, Liu S, Zhu H, Xie X, Jiang Y, Wu S, He W, Li Y. *Rheumatol Int*. 2017 Apr;37(4):585-592.

[High pneumococcal DNA load, procalcitonin and suPAR levels correlate to severe disease development in patients with pneumococcal pneumonia.](#)

Loonen AJ, Kesarsing C, Kusters R, Hilbink M, Wever PC, van den Brule AJ.  
Eur J Clin Microbiol Infect Dis. 2017 Mar 29. doi: 10.1007/s10096-017-2963-2.

[Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7.](#)

Pofi R, Fiore D, De Gaetano R, Panio G, Gianfrilli D, Pozza C, Barbagallo F, Xiang YK, Giannakakis K, Morano S, Lenzi A, Naro F, Isidori AM, Venneri MA. Sci Rep. 2017 Mar 15;7:44584.

[Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death.](#)

Ghasemzedah N, Hayek SS, Ko YA, Eapen DJ, Patel RS, Manocha P, Al Kassem H, Khayata M, Veledar E, Kremastinos D, Thorball CW, Pielak T, Sikora S, Zafari AM, Lerakis S, Sperling L, Vaccarino V, Epstein SE, Quyyumi AA. Circ Cardiovasc Qual Outcomes. 2017 Mar;10(3).

[The intriguing role of soluble urokinase receptor in inflammatory diseases.](#)

Desmedt S, Desmedt V, Delanghe JR, Speeckaert R, Speeckaert MM.  
Crit Rev Clin Lab Sci. 2017 Mar;54(2):117-133.

[Soluble Urokinase-type Plasminogen Activator Receptor \(suPAR\) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.](#)

Schulz CA, Persson M, Christensson A, Hindy G, Almgren P, Nilsson PM, Melander O, Engström G, Orho-Melander M. Kidney Int Rep. 2017 Mar;2(2):239-247.

[Usefulness of soluble urokinase plasminogen activator receptor \(suPAR\) as an inflammatory biomarker in obese children.](#)

Kosecik M, Dervisoglu P, Koroglu M, Isguven P, Elmas B, Demiray T, Altindis M. Int J Cardiol. 2017 Feb 1;228:158-161.

[Serum Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated with Low Left Ventricular Ejection Fraction and Elevated Plasma Brain-Type Natriuretic Peptide Level.](#)

Fujita SI, Tanaka S, Maeda D, Morita H, Fujisaka T, Takeda Y, Ito T, Ishizaka N. PLoS One. 2017 Jan 30;12(1):e0170546.

[Soluble urokinase receptor \(suPAR\) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.](#)

Guthoff M, Wagner R, Randrianarisoa E, Hatzigelaki E, Peter A, Häring HU, Fritsche A, Heyne N. Sci Rep. 2017 Jan 16;7:40627.

[Acute effects of moderate altitude on biomarkers of cardiovascular inflammation and endothelial function and their differential modulation by dual endothelin receptor blockade.](#)

Lichtenauer M, Goebel B, Paar V, Wernly B, Gecks T, Rohm I, Förster M, Betge S, Figulla HR, Hoppe UC, Kelm M, Franz M, Jung C. 2017

[Untreated Psoriasis Impairs Male Fertility: A Case-Control Study.](#)

Caldarola G, Milardi D, Grande G, Quercia A, Baroni S, Morelli R, Marana R, Pontecorvi A, De Simone C, Peris K. 2017



[Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients.](#)

Huang Y, Zhou H, Wu Y, Yang Y, Li W, Lu J, Hu Y. 2017

[Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.](#)

Dande RR, Peev V, Altintas MM, Reiser J. 2017

[Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.](#)

Fagerberg B, Borné Y, Barregard L, Sallsten G, Forsgard N, Hedblad B, Persson M, Engström G. Environ Res. 2017 Jan;152:185-191.

[Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR.](#)

Rudolf F, Wagner AJ, Back FM, Gomes VF, Aaby P, Østergaard L, Eugen-Olsen J, Wejse C. Int J Tuberc Lung Dis. 2017 Jan 1;21(1):67-72.

[Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.](#)

Hahm E, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, Wadhvani S, Cao Y, Peev V, Zloza A, Lusciks J, Hayek SS, O'Connor C, Bitzer M, Gupta V, Sever S, Sykes DB, Scadden DT, Reiser J. Nat Med. 2017 Jan;23(1):100-106.

[Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis.](#)

Nikkola A, Aittoniemi J, Huttunen R, Rajala L, Nordback I, Sand J, Laukkarinen J. Pancreas. 2017 Jan;46(1):77-82.

[Soluble urokinase-type plasminogen activator receptor \(suPAR\) in patients with acute pancreatitis \(AP\) - Progress in prediction of AP severity.](#)

Lipinski M, Rydzewska-Rosolowska A, Rydzewski A, Cicha M, Rydzewska G. Pancreatology. 2017 Jan - Feb;17(1):24-29.

**2016**

[Resveratrol Attenuates Adriamycin-Induced Focal Segmental Glomerulosclerosis through C3aR/C5aR-Sphingosine Kinase 1 Pathway.](#)

Liu G, Wang Q, Shi Y, Peng X, Liu H, Peng Y, He L. 2017

[Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.](#)

Ni W, Han Y, Zhao J, Cui J, Wang K, Wang R, Liu Y. Sci Rep. 2016 Dec 19

[Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor \(suPAR\) in patients with type 2 diabetes.](#)

Persson F, Theilade S, Eugen-Olsen J, Rossing P, Parving HH. J Diabetes Complications. 2016 Nov - Dec;30(8):1440-1442

[Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication.](#)

Tognoli E, Luigi Giuseppe Leoni M, Morelli D, Sottotetti E, Martinetti A, Signoroni S, Galeone C, Gallino G. Wound Repair Regen. 2016 Nov;24(6):1036-1040.

[The diagnostic value of soluble urokinase plasminogen activator receptor \(suPAR\) compared to C-reactive protein \(CRP\) and procalcitonin \(PCT\) in children with systemic inflammatory response syndrome \(SIRS\).](#)

Şirinoğlu M, Soysal A, Karaaslan A, Kepenekli Kadayıfci E, Yalındağ-Öztürk N, Cinel İ, Yaman A, Haklar G, Şirikci Ö, Turan S, Altınkanat Gelmez G, Söyletir G, Bakır M. J Infect Chemother. 2016 Oct 19

[Role of suPAR and Lactic Acid in Diagnosing Sepsis and Predicting Mortality in Elderly Patients.](#)

Khater WS, Salah-Eldeen NN, Khater MS, Saleh AN. Eur J Microbiol Immunol (Bp). 2016 Jul 19;6(3):178-185

[Acute Changes in Inflammatory Biomarker Levels in Recreational Runners Participating in a Marathon or Half-Marathon.](#)

Niemelä M, Kangastupa P, Niemelä O, Bloigu R, Juvonen T. Sports Med Open. 2016 Dec;2(1):21

[Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.](#)

Wang H, Yang T, Li D, Wu Y, Zhang X, Pang C, Zhang J, Ying B, Wang T, Wen F. Int J Chron Obstruct Pulmon Dis. 2016 Sep 26;11:2369-2376.

[The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor \(suPAR\) Levels in Autoimmune Connective Tissue Disorders.](#)

Vasarhelyi B, Toldi G, Balog A. EJIFCC. 2016 Apr 20;27(2):122-9.

[Soluble urokinase plasminogen activator receptor \(suPAR\) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.](#)

Rasmussen LJ, Ladelund S, Haupt TH, Ellekilde G, Poulsen JH, Iversen K, Eugen-Olsen J, Andersen O. Emerg Med J. 2016 Sep 2

[Involvement of urokinase receptor in the cross-talk between human hematopoietic stem cells and bone marrow microenvironment.](#)

Selleri C, Montuori N, Salvati A, Serio B, Pesapane A, Ricci P, Gorrasi A, Li Santi A, Hoyer-Hansen G, Ragno P. Oncotarget. 2016 Aug 8

[Inflammatory markers associated with abdominal aortic aneurysm.](#)

Lindberg S, Zarrouk M, Holst J, Gottsäter A. 2016 Sep 1

[Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.](#)

Kronbichler A, Saleem MA, Meijers B, Shin JI. J Immunol Res. 2016;2016:2068691

[SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis.](#)

Hodges GW, Bang CN, Eugen-Olsen J, Olsen MH, Boman K, Ray S, Gohlke-Bärwolf C, Kesäniemi YA, Jeppesen JL, Wachtell K. Can J Cardiol. 2016 May 3.

[Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial.](#)

Sandø A, Schultz M, Eugen-Olsen J, Rasmussen LS, Køber L, Kjølner E, Jensen BN, Ravn L, Lange T, Iversen K. Scand J Trauma Resusc Emerg Med. 2016 Aug 5;24:100



[Prognostic significance of APACHE II score and plasma suPAR in Chinese patients with sepsis: a prospective observational study.](#)

Liu X, Shen Y, Li Z, Fei A, Wang H, Ge Q, Pan S. BMC Anesthesiol. 2016 Jul 29;16(1):46

[Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study.](#)

Lindboe JB, Langkilde A, Eugen-Olsen J, Hansen BR, Haupt TH, Petersen J, Andersen O. Infect Dis (Lond). 2016 Nov-Dec;48(11-12):829-37

[Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema.](#)

Hilty MP, Zügel S, Schoeb M, Auinger K, Dehnert C, Maggiorini M. Mediators Inflamm. 2016;2016:1942460.

[Plasma levels of eight different mediators and their potential as biomarkers of various clinical malaria conditions in African children.](#)

Tahar R, Albergaria C, Zeghidour N, Ngane VF, Basco LK, Roussilhon C. Malar J. 2016 Jun 29;15:337

[Diagnostic Value of Upar, IL-33, and ST2 Levels in Childhood Sepsis.](#)

Çekmez F, Fidancı MK, Ayar G, Saldır M, Karaoglu A, Gündüz RC, Tunc T, Kalkan G. Clin Lab. 2016;62(5):751-5.

[Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy: A Retrospective Observational Study.](#)

Gu QH, Cui Z, Huang J, Zhang YM, Qu Z, Wang F, Wang X, Wang SX, Liu G, Zhao MH. Medicine (Baltimore). 2016 May;95(21):e3786

[Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates.](#)

Königshausen E, Sellin L. Biomed Res Int. 2016;2016:3765608.

[Plasma-soluble urokinase plasminogen activator receptor \(suPAR\) levels in Behçet's disease and correlation with disease activity.](#)

Saylam Kurtipek G, Kesli R, Tuncez Akyurek F, Akyurek F, Ataseven A, Terzi Y. Int J Rheum Dis. 2016 May 12.

[Soluble urokinase plasminogen activator receptor informs on the progression course after multiple injuries.](#)

Patrani M, Tsaganos T, Kotzampassi K, Paraschos M, Katsenos C, Giamarellos-Bourboulis EJ, Mandragos K. Biomarkers. 2016 Nov;21(7):660-4.

[Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis.](#)

Soltysiak J, Zachwieja J, Benedyk A, Lewandowska-Stachowiak M, Nowicki M, Ostalska-Nowicka D. Minerva Pediatr. 2016 Apr 12.

[Usefulness of sCD14-ST in the diagnosis of sepsis in patient with renal failure.](#)

Galeano D, Zanolli L, Fatuzzo P, Granata A. G Ital Nefrol. 2016 Mar-Apr;33(2).

[The diagnostic value of soluble urokinase plasminogen activator receptor compared with C-reactive protein and procalcitonin in children with febrile neutropenia.](#)

Sirinoglu M, Soysal A, Karaaslan A, Kadayifci EK, Cinel I, Koç A, Tokuç G, Yaman A, Haklar G, Şirikçi Ö, Turan S, Gelmez GA, Söyletir G, Bakır M. *Pediatr Hematol Oncol.* **2016** Apr 8:1-9.

[Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness.](#)

Cyrille NB, Villablanca PA, Ramakrishna H. *Ann Card Anaesth.* **2016** Apr-Jun;19(2):214-6.

[From lactate to soluble urokinase plasminogen activator receptor: The journey for ideal cardiac biomarker: Are we there in 2016?](#)

[A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.](#)

Leandersson P, Kalapotharakos G, Henic E, Borgfeldt H, Petzold M, Høyer-Hansen G, Borgfeldt C. *Anticancer Res.* **2016** Mar;36(3):957-65.

[Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.](#)

El-Mekawy MS, Saleh NY, Sonbol AA. *Indian J Pediatr.* **2016** Mar 10.

[Plasma soluble urokinase plasminogen activator receptor \(suPAR\) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.](#)

Theilade S, Rossing P, Eugen-Olsen J, Jensen JS, Jensen MT. *Eur J Endocrinol.* **2016** Mar 7.

[Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.](#)

Chen JS, Chang LC, Wu CZ, Tseng TL, Lin JA, Lin YF, Cheng CW. *J Biomed Sci.* **2016** Feb 4;23(1):24.

[Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial.](#)

Kasang C, Kalluvya S, Majinge C, Kongola G, Mlewa M, Massawe I, Kabyemera R, Magambo K, Ulmer A, Klinker H, Gschmack E, Horn A, Koutsilieri E, Preiser W, Hofmann D, Hain J, Müller A, Dölken L, Weissbrich B, Rethwilm A, Stich A, Scheller C. *PLoS One.* **2016** Jan 26;11(1):e0146678.

[Plasma suPAR is lowered by smoking cessation: a randomized controlled study.](#)

Eugen-Olsen J, Ladelund S, Sørensen LT. *Eur J Clin Invest.* **2016** Apr;46(4):305-11.

[Serum soluble urokinase-type plasminogen activator receptor levels in male patients with acute exacerbation of schizophrenia.](#)

Genc A, Kalelioglu T, Karamustafalioglu N, Tasdemir A, Genc ES, Akkus M, Emul M. *Psychiatry Res.* **2016** Feb 28;236:179-81.

[Thrombocytopenia in critically ill patients with severe sepsis/septic shock: Prognostic value and association with a distinct serum cytokine profile.](#)

Tsirigotis P, Chondropoulos S, Frantzeskaki F, Stamouli M, Gkirkas K, Bartzeliotou A, Papanikolaou N, Atta M, Papassotiriou I, Dimitriadis G, Dimopoulou I. *J Crit Care.* **2016** Apr;32:9-15.

[Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis.](#)

Zeng M, Chang M, Zheng H, Li B, Chen Y, He W, Huang C. Am J Emerg Med. **2016** Mar;34(3):375-80.

[Chronic kidney disease: suPAR in CKD.](#)

Allison SJ. Nat Rev Nephrol. **2016** Jan;12(1):3.

[Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B.](#)

Sevgi DY, Bayraktar B, Gündüz A, Özgüven BY, Togay A, Bulut E, Uzun N, Dökmetaş İ. Wien Klin Wochenschr. **2016** Jan;128(1-2):28-33.

[Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.](#)

Engström G, Zöller B, Svensson PJ, Melander O, Persson M. Thromb Haemost. **2016** Feb 29;115(3):657-62.

[Sclerostin, TNF-alpha and Interleukin-18 Correlate and are Together with Klotho Related to Other Growth Factors and Cytokines in Haemodialysis Patients.](#)

Almroth G, Lönn J, Uhlin F, Brudin L, Andersson B, Hahn-Zoric M. Scand J Immunol. **2016** Jan;83(1):58-63.

[The glomerular permeability factors in idiopathic nephrotic syndrome.](#)

Davin JC. Pediatr Nephrol. **2016** Feb;31(2):207-15.

[Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions.](#)

Ozsu S, Oztuna F, Mentese A, Abul Y, Ozlu T. Clin Respir J. **2016** Jan;10(1):61-6.

## **2015**

[Thrombocytopenia in critically ill patients with severe sepsis/septic shock: Prognostic value and association with a distinct serum cytokine profile.](#)

Tsirigotis P, Chondropoulos S, Frantzeskaki F, Stamouli M, Gkirkas K, Bartzeliotou A, Papanikolaou N, Atta M, Papassotiriou I, Dimitriadis G, Dimopoulou I. J Crit Care. 2015 Nov 22.

[Plasma-soluble urokinase plasminogen activator receptor \(suPAR\) levels in psoriasis patients and correlation with disease severity.](#)

Kurtipek GS, Kesli R, Tunçez Akyürek F, Akyüret F, Terzi Y. Acta Dermatovenerol Alp Pannonica Adriat. 2015 Dec;24(4):73-5.

[Circulating CD40 autoantibody and suPAR synergy drives glomerular injury.](#)

[Wei C, Sigdel TK, Sarwal MM, Reiser J.](#)

Ann Transl Med. 2015 Nov;3(19):300.

[Association among Fibrinolytic Proteins, Metabolic Syndrome Components, Insulin Secretion, and Resistance in Schoolchildren.](#)

Chen JS, Wu CZ, Chu NF, Chang LC, Pei D, Lin YF. Int J Endocrinol. **2015**;2015:170987. **2015** Nov 8.

[Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis.](#)

Shen J, Wang Q, Wang J, Su GH, Wang J, Guo SH, Liu YA, Wu Z, Liu RF, Li X, Guo XJ, Cao J, Zhang YH, Wang ZY. Oncol Lett. **2015** Oct;10(4):2403-2409.

[Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis.](#)

Zeng M, Chang M, Zheng H, Li B, Chen Y, He W, Huang C. Am J Emerg Med. **2015** Nov 9.

[A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues.](#)

Wada T, Nangaku M. Clin Kidney J. **2015** Dec;8(6):708-715.

[suPAR: The unspecific marker for disease presence, severity and prognosis.](#)

Eugen-Olsen J, Giamarellos-Bourboulis EJ. Int J Antimicrob Agents. **2015** Oct 31.

[Chronic kidney disease: suPAR in CKD.](#)

Allison SJ. Nat Rev Nephrol. **2015** Nov 23.

[Serum soluble urokinase-type plasminogen activator receptor and interferon- \$\gamma\$ -induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B.](#)

Sevgi DY, Bayraktar B, Gündüz A, Özgüven BY, Togay A, Bulut E, Uzun N, Dökmetaş İ. Wien Klin Wochenschr. **2015** Nov 6.

[Soluble Urokinase Receptor and Chronic Kidney Disease.](#)

Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J. N Engl J Med. **2015** Nov 12;373(20):1916-25.

[A suPAR Biomarker for Chronic Kidney Disease.](#)

Skorecki KL, Freedman BI. N Engl J Med. **2015** Nov 12;373(20):1971-2.

[Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.](#)

Engström G, Zöller B, Svensson PJ, Melander O, Persson M. Thromb Haemost. **2015** Oct 15;115(3)

[Increased Soluble Urokinase-Type Plasminogen Activator Receptor \(suPAR\) Levels in Plasma of Suicide Attempters.](#)

Ventorp F, Gustafsson A, Träskman-Bendz L, Westrin Å, Ljunggren L. PLoS One. **2015** Oct 9;10(10):e0140052.

[Sclerostin, TNF-alpha and interleukin-18 correlate and are together with Klotho related to other growth factors and cytokines in hemodialysis patients.](#)

Almroth G, Lönn J, Uhlin F, Brudin L, Andersson B, Hahn-Zoric M. Scand J Immunol. **2015** Oct 8.

[suPAR as a biomarker for risk of readmission and mortality in the acute medical setting.](#)

Nayak RK, Allingstrup M, Phanareth K, Kofoed-Enevoldsen A. Dan Med J. **2015** Oct;62(10).

[suPAR: A Cardiac Biomarker With a Future?](#)

Arbel Y, Strauss BH. Can J Cardiol. **2015** Oct;31(10):1223-4.

[Soluble urokinase-type plasminogen activator receptor as a putative marker of male accessory gland inflammation.](#)

Autilio C, Morelli R, Milardi D, Grande G, Marana R, Pontecorvi A, Zuppi C, Baroni S. Andrology. **2015** Sep 18.

[Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.](#)

Guo SM, Han M, Chen MX, Ning Y, Pei GC, Li YQ, Dai W, Ge SW, Deng YJ, Guo YY, Li XQ, Haller H, Xu G, Rong S. PLoS One. **2015** Sep 18;10(9):e0138718.

[Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.](#)

Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, Danese S, D'Alessio S, Genua M, Portale F, Lo Porto M, Singhal PC, Rastaldi MP, Saleem MA, Mavilio D, Mikulak J. Sci Rep. **2015** Sep 18;5:13647.

[The Prognostic Significance Of Soluble Urokinase Plasminogen Activator Receptor In Acute Myeloid Leukemia.](#)

Erkut N, Mentese A, Ozbas HM, Ermantas N, Sumer A, Orem A, Sonmez M. Turk J Haematol. **2015** Aug 6.

[Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte  \$\beta\$ 3-integrin Activation.](#)

Staeck O, Slowinski T, Lieker I, Wu K, Rudolph B, Schmidt D, Brakemeier S, Neumayer HH, Wei C, Reiser J, Budde K, Halleck F, Khadzhyrov D. Transplantation. **2015** Dec;99(12):2593-7.

[Soluble urokinase plasminogen activator receptor \(suPAR\) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.](#)

Rasmussen L, Knudsen A, Katzenstein TL, Gerstoft J, Obel N, Jørgensen NR, Kronborg G, Benfield T, Kjaer A, Eugen-Olsen J, Lebech AM. HIV Med. **2015** Sep 14.

[Three-year changes of prothrombotic factors in a cohort of South Africans with a high clinical suspicion of obstructive sleep apnea.](#)

von Känel R, Malan NT, Hamer M, Lambert GW, Schlaich M, Reimann M, Malan L. Thromb Haemost. **2015** Sep 3;115(1).

[Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.](#)

Jin J, Li YW, He Q. Transplant Proc. **2015** Jul-Aug;47(6):1760-5.

[Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls.](#)

Langkilde A, Petersen J, Henriksen JH, Jensen FK, Gerstoft J, Eugen-Olsen J, Andersen O. Immun Ageing. **2015** Aug 4;12:9.

[Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.](#)

Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS. BMC Nephrol. **2015** Jul 22;16:111.

[Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.](#)

Zhao Y, Liu L, Huang J, Shi S, Lv J, Liu G, Zhao M, Zhang H. PLoS One. **2015** Jul 13;10(7):e0132869.

[Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.](#)

Wu CZ, Chang LC, Lin YF, Hung YJ, Pei D, Chu NF, Chen JS. Clin Biochem. **2015** Jul 8.

[Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department.](#)

Casagrande I, Vendramin C, Callegari T, Vidali M, Calabresi A, Ferrandu G, Cervellin G, Cavazza M, Lippi G, Zanotti I, Negro S, Rocchetti A, Arfini C. Intern Emerg Med. **2015** Sep;10(6):725-30.

[Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.](#)

Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A. BMC Cancer. **2015** Jul 1;15:492.

[suPAR: A New Biomarker for Cardiovascular Disease?](#)

Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL. Can J Cardiol. **2015** Oct;31(10):1293-302.

[1C.01: SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A PROGNOSTIC MARKER OF ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN A BLACK POPULATION.](#)

Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Pretorius R, Schutte AE. J Hypertens. **2015** Jun;33 Suppl 1:e9.

[9A.06: IMPACT OF METABOLIC, HEMODYNAMIC AND INFLAMMATORY FACTORS ON TARGET ORGAN DAMAGE IN HEALTHY SUBJECTS.](#)

Blicher M, Kruger R, Olesen T, Greve S, Hansen T, Olsen MH. J Hypertens. **2015** Jun;33 Suppl 1:e118.

[Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients.](#)

Geboers DG, de Beer FM, Tuip-de Boer AM, van der Poll T, Horn J, Cremer OL, Bonten MJ, Ong DS, Schultz MJ, Bos LD. Intensive Care Med. **2015** Jul;41(7):1281-90.

[Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence.](#)

Mujtaba MA, Sharfuddin AA, Book BL, Goggins WC, Khalil AA, Mishler DP, Fridell JA, Yaqub MS, Taber TE. Clin Transplant. 2015 May 12.

[PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis.](#)

Unselde M, Chilla A, Pausz C, Mawas R, Breuss J, Zielinski C, Schabbauer G, Prager GW. Thromb Haemost. 2015 Apr 30;114(2).

[The glomerular permeability factors in idiopathic nephrotic syndrome.](#)

Davin JC. Pediatr Nephrol. 2015 Apr 30.

[Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis.](#)

Legány N, Toldi G, Distler JH, Beyer C, Szalay B, Kovács L, Vásárhelyi B, Balog A. Clin Chem Lab Med. 2015 Apr 18.

[A case report of adrenocorticotrophic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring.](#)

Anwar S, Larson DS, Naimi N, Ashraf M, Culiberk N, Liapis H, Wei C, Reiser J, Brennan DC. Front Med (Lausanne). 2015 Mar 20;2:13.



[Soluble uPAR is released selectively by glioblastoma cells that express EGF receptor variant III and promotes tumor cell migration and invasion.](#)

Gilder AS, Jones KA, Hu J, Wang L, Chen CC, Carter BS, Gonias SL. J Biol Chem. 2015 Apr 2.

[Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.](#)

Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Pretorius R, Schutte AE. Int J Cardiol. 2015 Apr 1;184:631-6.

[Role of formic receptors in soluble urokinase receptor-induced human vascular smooth muscle migration.](#)

Duru EA, Fu Y, Davies MG. J Surg Res. 2015 May 15;195(2):396-405.

[The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.](#)

Wach S, Al-Janabi O, Weigelt K, Fischer K, Greither T, Marcou M, Theil G, Nolte E, Holzhausen HJ, Stöhr R, Huppert V, Hartmann A, Fornara P, Wullich B, Taubert H. Int J Cancer. 2015 Mar 6.

[Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.](#)

Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Schutte AE. Hypertens Res. 2015 Mar 5.

[Soluble urokinase-type plasminogen activator levels are related to plasma cytokine levels but have low predictive value for mortality in trauma patients.](#)

Timmermans K, Vaneker M, Scheffer GJ, Maassen P, Janssen S, Kox M, Pickkers P. J Crit Care. 2015 Jun;30(3):476-80.

[Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.](#)

Gumus A, Altintas N, Cinarka H, Kirbas A, Hazıroglu M, Karatas M, Sahin U. Int J Chron Obstruct Pulmon Dis. 2015 Feb 13;10:357-65.

[Soluble urokinase plasminogen activator receptor-A valuable biomarker in systemic lupus erythematosus?](#)

Enocsson H, Sjöwall C, Wetterö J. Clin Chim Acta. 2015 Feb 19.

[The Inflammatory Marker suPAR After Cardiac Arrest.](#)

Rundgren M, Lyngbaek S, Fisker H, Friberg H. Ther Hypothermia Temp Manag. 2015 Feb 19.

[Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.](#)

Tarpgaard LS, Christensen IJ, Høyer-Hansen G, Lund IK, Guren TK, Glimelius B, Sorbye H, Tveit KM, Nielsen HJ, Moreira JM, Pfeiffer P, Brünnner N. Int J Cancer. 2015 Feb 9.

[The role of the soluble urokinase plasminogen activator \(suPAR\) in children with pneumonia.](#)

Wrotek A, Jackowska T. Respir Physiol Neurobiol. 2015 Apr;209:120-3.

[Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.](#)

Mekonnen G, Corban MT, Hung OY, Eshtehardi P, Eapen DJ, Al-Kassem H, Rasoul-Arzrumly E, Gogas BD, McDaniel MC, Pielak T, Thorball CW, Sperling L, Quyyumi AA, Samady H.

Atherosclerosis. 2015 Mar;239(1):55-60.

[Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.](#)

Park MY, Herrmann SM, Saad A, Eirin A, Tang H, Lerman A, Textor SC, Lerman LO.  
Clin J Am Soc Nephrol. 2015 Mar 6;10(3):443-51.

[Clinical significance of serum and urinary soluble urokinase receptor \(suPAR\) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.](#)

Fujimoto K, Imura J, Atsumi H, Matsui Y, Adachi H, Okuyama H, Yamaya H, Yokoyama H.  
Clin Exp Nephrol. 2015 Oct;19(5):804-14.

[Soluble urokinase-type plasminogen activator receptor \(suPAR\) as new biomarker of the prosthetic joint infection: Correlation with inflammatory cytokines.](#)

Galliera E, Drago L, Marazzi MG, Romanò C, Vassena C, Corsi Romanelli MM.  
Clin Chim Acta. 2015 Feb 20;441:23-8.

[Extracellular Matrix Biomarker, Fibulin-1 and Its Association with Soluble uPAR in a Bi-ethnic South African Population: The SAfrEIC Study.](#)

du Plooy CS, Kruger R, Huisman HW, Rasmussen LM, Eugen-Olsen J, Schutte AE.  
Heart Lung Circ. 2015 Mar;24(3):298-305.

[Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.](#)

Sjöwall C, Martinsson K, Cardell K, Ekstedt M, Kechagias S. Transl Res. 2015 Jun;165(6):658-66.

[A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.](#)

Spinale JM, Mariani LH, Kapoor S, Zhang J, Weyant R, Song PX, Wong HN, Troost JP, Gadegbeku CA, Gipson DS, Kretzler M, Nihalani D, Holzman LB; Investigators of the Nephrotic Syndrome Study Network.  
Kidney Int. 2015 Mar;87(3):564-74.

[Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.](#)

Chounta A, Ellinas C, Tzanetakou V, Pliarhopoulou F, Mplani V, Oikonomou A, Leventogiannis K, Giamarellos-Bourboulis EJ. Liver Int. 2015 Feb;35(2):601-7.

[Host response biomarker in sepsis: suPAR detection.](#)

Giamarellos-Bourboulis EJ, Georgitsi M. Methods Mol Biol. 2015;1237:241-6.

[Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children.](#)

Wrotek A, Jackowska T, Pawlik K. Adv Exp Med Biol. 2015;835:1-7.

[Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.](#)

Musetti C, Quaglia M, Cena T, Chiocchetti A, Monti S, Clemente N, Magnani C, Dianzani U, Stratta P.  
J Nephrol. 2015 Jun;28(3):299-305.

[Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia.](#)

Nielsen J, Røge R, Pristed SG, Viuff AG, Ullum H, Thørner LW, Werge T, Vang T.  
Schizophr Bull. 2015 May;41(3):764-71.

[Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis.](#)  
Okulu E, Arsan S, Akin IM, Ates C, Alan S, Kilic A, Atasay B. J Clin Lab Anal. **2015** Sep;29(5):347-52.

[Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.](#)

Peng Z, Mao J, Chen X, Cai F, Gu W, Fu H, Shen H, Wang J, Jin X, Zhu X, Liu A, Shu Q, Du L.  
Pediatr Nephrol. 2015 Feb;30(2):301-7.

[Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release.](#)

Vaschetto R, Navalesi P, Clemente N, Boggio E, Valsecchi S, Olivieri C, Soluri MF, Kroumova V, Fonio P, Dinatale C, Borrè S, Fortina G, Umberto D, Della Corte F, Chiocchetti A.  
Minerva Anestesiol. 2015 Feb;81(2):157-65.

[Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.](#)

Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, Mitrofanova A, Leclercq F, Faul C, Li J, Kretzler M, Nelson RG, Lehto M, Forsblom C, Groop PH, Reiser J, Burke GW, Fornoni A, Merscher S.  
J Am Soc Nephrol. 2015 Jan;26(1):133-47.

[Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.](#)

Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, Naesens M, Storr M, Kuypers D, Evenepoel P. Kidney Int. **2015** Jan;87(1):210-6.

[Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.](#)

Theilade S, Lyngbaek S, Hansen TW, Eugen-Olsen J, Fenger M, Rossing P, Jeppesen JL.  
J Intern Med. 2015 Mar;277(3):362-71.

## **2014**

[Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.](#)

Usnarska-Zubkiewicz L, Strutyńska-Karpińska M, Zubkiewicz-Kucharska A, Zarębski P, Grabowski K. Adv Clin Exp Med. 2014 Nov-Dec;23(6):959-67.

[Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.](#)

Haupt TH, Kallemose T, Ladelund S, Rasmussen LJ, Thorball CW, Andersen O, Pisinger C, Eugen-Olsen J.  
Biomark Insights. 2014 Dec 16;9:91-100.

[Biomarkers of Kidney Injury and Klotho in Patients with Atherosclerotic Renovascular Disease.](#)

Park MY, Herrmann SM, Saad A, Eirin A, Tang H, Lerman A, Textor SC, Lerman LO.  
Clin J Am Soc Nephrol. 2014 Dec 26

[p-Cresol Affects Reactive Oxygen Species Generation, Cell Cycle Arrest, Cytotoxicity and Inflammation/Atherosclerosis-Related Modulators Production in Endothelial Cells and Mononuclear Cells.](#)

Chang MC, Chang HH, Chan CP, Yeung SY, Hsien HC, Lin BR, Yeh CY, Tseng WY, Tseng SK, Jeng JH.  
PLoS One. 2014 Dec 17;9(12):e114446.

[Clinical significance of serum and urinary soluble urokinase receptor \(suPAR\) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.](#)

Fujimoto K, Imura J, Atsumi H, Matsui Y, Adachi H, Okuyama H, Yamaya H, Yokoyama H. Clin Exp Nephrol. 2014 Dec 13.

[Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.](#)

Sjöwall C, Martinsson K, Cardell K, Ekstedt M, Kechagias S. Transl Res. 2014 Oct 5.

[Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future.](#)

Maas RJ, Deegens JK, Wetzels JF. Nephrol Dial Transplant. 2014 Dec;29(12):2207-16.

[Diagnostic and prognostic significance of suPAR in traumatic brain injury.](#)

Yu L, Wu X, Wang H, Long D, Yang J, Zhang Y. Neurol India. 2014 Sep-Oct;62(5):498-502.

[Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.](#)

Eapen DJ, Manocha P, Ghasemzedah N, Patel RS, Al Kassem H, Hammadah M, Veledar E, Le NA, Pielak T, Thorball CW, Velegiraki A, Kremastinos DT, Lerakis S, Sperling L, Quyyumi AA. J Am Heart Assoc. 2014 Oct 23;3(5):e001118.

[Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants.](#)

Haastrup E, Grau K, Eugen-Olsen J, Thorball C, Kessing LV, Ullum H. PLoS One. 2014 Oct 20;9(10):e110555.

[Host Response Biomarker in Sepsis: suPAR Detection.](#)

Giamarellos-Bourboulis EJ, Georgitsi M. Methods Mol Biol. 2015;1237:241-6.

[Relationship between Serum Soluble Urokinase Plasminogen Activator Receptor Level and Steroid Responsiveness in FSGS.](#)

Li F, Zheng C, Zhong Y, Zeng C, Xu F, Yin R, Jiang Q, Zhou M, Liu Z. Clin J Am Soc Nephrol. 2014 Oct 15.

[Soluble Urokinase Plasminogen Activator Receptor: An Indicator of Pneumonia Severity in Children.](#)

Wrotek A, Jackowska T, Pawlik K. Adv Exp Med Biol. 2014 Oct 15.

[A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.](#)

Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM. Sci Transl Med. 2014 Oct 1;6(256):256ra136.

[Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.](#)

Sørensen MH, Gerke O, Eugen-Olsen J, Munkholm H, Lambrechtsen J, Sand NP, Mickley H, Rasmussen LM, Olsen MH, Diederichsen A. Atherosclerosis. 2014 Sep 2;237(1):60-66.

[Diabetes mellitus in the transplanted kidney.](#)

Peev V, Reiser J, Alachkar N. Front Endocrinol (Lausanne). 2014 Aug 27;5:141.

[The predictive value of soluble urokinase plasminogen activator receptor \(SuPAR\) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.](#)

Ville J, Jukka V, Ville P, Jouni K, Tero V, Marjaana T, Heini H, Ari A, Seppo H, Outi K, Anne K, Jyrki T; The FINNRESUSCI LAB STUDY GROUP. Resuscitation. 2014 Sep 2.

[Clinical evaluation of multiple inflammation biomarkers for diagnosis and prognosis for patients with systemic inflammatory response syndrome.](#)

Reichsoellner M, Raggam RB, Wagner J, Krause R, Hoenigl M. J Clin Microbiol. 2014 Nov;52(11):4063-6.

[Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.](#)

Musetti C, Quaglia M, Cena T, Chiochetti A, Monti S, Clemente N, Magnani C, Dianzani U, Stratta P. J Nephrol. 2014 Sep 4.

[Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor.](#)

Lin Y, Peng N, Zhuang H, Zhang D, Wang Y, Hua ZC. BMC Cancer. 2014 Aug 30;14:639.

[Permeability factors in focal and segmental glomerulosclerosis.](#)

Reiser J, Nast CC, Alachkar N. Adv Chronic Kidney Dis. 2014 Sep;21(5):417-21.

[Reply: Measurement of serum suPAR is not ready for clinical use.](#)

Deegens J, Wetzels J. Nat Rev Nephrol. 2014 Oct;10(10):610

[suPAR and Team Nephrology.](#)

Trachtman H. BMC Med. 2014 May 20;12(1):82.

[Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.](#)

Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Zhao MH. BMC Med. 2014 May 20;12(1):81.

[Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis: a prospective study.](#)

Sihanidou T, Margeli A, Tsirogianni C, Charoni S, Giannaki M, Vavourakis E, Charisiadou A, Papassotiriou I. Mediators Inflamm. 2014;2014:375702.

[Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.](#)

Al-Janabi O, Taubert H, Lohse-Fischer A, Fröhner M, Wach S, Stöhr R, Keck B, Burger M, Wieland W, Erdmann K, Wirth MP, Wullich B, Baretton G, Magdolen V, Kotzsch M, Füssel S. Biomed Res Int. 2014;2014:972587.

[CD80 and suPAR: Diagnostic and pathogenic value in minimal change disease and focal segmental glomerulosclerosis?](#)

Davin JC. Pediatr Nephrol. 2014 May 17.

[CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance: Response.](#)

Cara-Fuentes G, Johnson RJ, Reiser J, Garin EH. *Pediatr Nephrol.* 2014 May 11.

[Associations of suPAR with lifestyle and cardiometabolic risk factors.](#)

Botha S, Fourie CM, Schutte R, Kruger A, Schutte AE. *Eur J Clin Invest.* 2014 May 8.

[Biomarkers for Sepsis.](#)

Henriquez-Camacho C, Losa J. *Biomed Res Int.* 2014;2014:547818.

[Administration of Recombinant Soluble Urokinase Receptor Per Se Is Not Sufficient to Induce Podocyte Alterations and Proteinuria in Mice.](#)

Cathelin D, Placier S, Ploug M, Verpont MC, Vandermeersch S, Luque Y, Hertig A, Rondeau E, Mesnard L. *J Am Soc Nephrol.* 2014 May 1.

[Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.](#)

Outinen TK, Mäkelä S, Huttunen R, Mäenpää N, Libraty D, Vaheri A, Mustonen J, Aittoniemi J. *J Intern Med.* 2014 Apr 10.

[suPAR and focal segmental glomerulosclerosis.](#)

Praga M. *Nefrologia.* 2014 Mar 19;34(2):145-148.

[Soluble Urokinase Plasminogen Activator Receptor \(suPAR\) predicts mortality in patients with Systemic Inflammatory Response Syndrome \(SIRS\).](#)

Raggam RB, Wagner J, Prüller F, Grisold A, Leitner E, Zollner-Schwetz I, Valentin T, Krause R, Hoenigl M. *J Intern Med.* 2014 Mar 19.

[Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria.](#)

Plewes K, Royakkers AA, Hanson J, Hasan MM, Alam S, Ghose A, Maude RJ, Stassen PM, Charunwatthana P, Lee SJ, Turner GD, Dondorp AM, Schultz MJ. *Malar J.* 2014 Mar 12;13(1):91.

[Predictive Value of Soluble Urokinase Plasminogen Activator Receptor, Soluble ST2 and IL-33 in Bronchopulmonary Dysplasia.](#)

Tunc T, Cekmez F, Yildirim S, Bulut O, Ince Z, Saldir M, Aydemir G, Yaman H, Coban A. *Pediatr Res.* 2014 Mar 6.

[Relevance of novel inflammatory markers in stroke-induced immunosuppression.](#)

Folyovich A, Biró E, Orbán C, Bajnok A, Varga V, Béres-Molnár AK, Vásárhelyi B, Toldi G. *BMC Neurol.* 2014 Mar 6;14(1):41.

[Serum suPAR concentrations in patients with focal segmental glomerulosclerosis with end-stage renal disease.](#)

Maas RJ, Wetzels JF, Deegens JK. *Kidney Int.* 2014 Mar;85(3):711.

[Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?](#)

Schlöndorff D. *Kidney Int.* 2014 Mar;85(3):499-501.



[Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor \(suPAR\) in acute liver failure.](#)

Koch A, Zimmermann HW, Gassler N, Jochum C, Weiskirchen R, Bruensing J, Buendgens L, Dückers H, Bruns T, Gerken G, Neumann UP, Adams DH, Trautwein C, Canbay A, Tacke F. Liver Int. 2014 Feb 28.

[SuPAR in pleural fluid may function as a biological marker for infection in critically ill patients with pleural effusions.](#)

Bakker OG, Hemmes SN, Backes Y, Determann RM, Schultz MJ. J Infect. 2014 Feb 15.

[Biomarkers and molecular analysis to improve bloodstream infection diagnostics in an emergency care unit.](#)

Loonen AJ, de Jager CP, Tossierams J, Kusters R, Hilbink M, Wever PC, van den Brule AJ. PLoS One. 2014 Jan 27;9(1):e87315.

[Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.](#)

Borné Y, Persson M, Melander O, Smith JG, Engström G. Eur J Heart Fail. 2014 Jan 23.

[\[Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis\].](#)

Segarra A, Jatem E, Quiles MT, Arbós MA, Ostos H, Valtierra N, Carnicer C, Salcedo MT. Nefrologia. 2014;34(1):53-61.

[\[Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome\].](#)

Segarra A, Jatem E, Quiles MT, Arbós MA, Ostos H, Valtierra N, Carnicer C, Agraz I, Salcedo MT. Nefrologia. 2014;34(1):46-52.

[Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.](#)

Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, Dinda AK, Agarwal SK, Sopory S, Pandey RM, Hari P, Bagga A. Kidney Int. 2014 Mar;85(3):649-58.

[A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.](#)

Wada T, Nangaku M, Maruyama S, Imai E, Shoji K, Kato S, Endo T, Muso E, Kamata K, Yokoyama H, Fujimoto K, Obata Y, Nishino T, Kato H, Uchida S, Sasatomi Y, Saito T, Matsuo S. Kidney Int. 2014 Mar;85(3):641-8.

[The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.](#)

Meijers B, Maas RJ, Sprangers B, Claes K, Poesen R, Bammens B, Naesens M, Deegens JK, Dietrich R, Storr M, Wetzels JF, Evenepoel P, Kuypers D. Kidney Int. 2014 Mar;85(3):636-40.

[Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.](#)

Fujimura K, Ebinuma H, Fukamachi I, Ohwada C, Kawaguchi T, Shimizu N, Takeuchi M, Sakaida E, Jiang M, Nakaseko C, Bujo H. Clin Chim Acta. 2014 Mar 20;430:48-54.

## **2013**

[Cardiac and proinflammatory markers predict prognosis in cirrhosis.](#)

Wiese S, Mortensen C, Gøtze JP, Christensen E, Andersen O, Bendtsen F, Møller S.

Liver Int. 2013 Dec 7. – [suPARnostic®](#)

[Life-long endurance exercise in humans: Circulating levels of inflammatory markers and leg muscle size.](#)

Mikkelsen UR, Couppé C, Karlsen A, Grosset JF, Schjerling P, Mackey AL, Klausen HH, Magnusson SP, Kjær M. Mech Ageing Dev. 2013 Nov 25. – [suPARnostic®](#)

[CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.](#)

Cara-Fuentes G, Wei C, Segarra A, Ishimoto T, Rivard C, Johnson RJ, Reiser J, Garin EH. Pediatr Nephrol. 2013 Nov 22.

[Soluble Urokinase Plasminogen Activator Receptor: A Risk Factor for Carotid Plaque, Stroke, and Coronary Artery Disease.](#)

Persson M, Ostling G, Smith G, Hamrefors V, Melander O, Hedblad B, Engström G. Stroke. 2013 Nov 19. – [suPARnostic®](#)

[Protein A immunoabsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis.](#)

Beaudreuil S, Zhang X, Kriaa F, Dantal J, Francois H, Vazquez A, Charpentier B, Lorenzo HK, Durrbach A. Nephrol Dial Transplant. 2013 Nov 13.

[Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients.](#)

Donadello K, Scolletta S, Taccone FS, Covajes C, Santonocito C, Cortes DO, Grazulyte D, Gottin L, Vincent JL. J Crit Care. 2013 Oct 8. – [suPARnostic®](#)

[Nanomechanical recognition of prognostic biomarker suPAR with DVD-ROM optical technology.](#)

Bache M, Bosco FG, Brøgger AL, Frøhling KB, Alstrøm TS, Hwu ET, Chen CH, Eugen-Olsen J, Hwang IS, Boisen A. Nanotechnology. 2013 Nov 8;24(44):444011. – [suPARnostic®](#)

[CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation.](#)

Cara-Fuentes G, Araya C, Wei C, Rivard C, Ishimoto T, Reiser J, Johnson RJ, Garin EH. Nefrologia. 2013;33(5):727-31.

[Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute puumala hantavirus infection.](#)

Outinen TK, Tervo L, Mäkelä S, Huttunen R, Mäenpää N, Huhtala H, Vaheri A, Mustonen J, Aittoniemi J. PLoS One. 2013 Aug 21;8(8):e71335.

[Recurrence of glomerulonephritis after renal transplantation.](#)

Sprangers B, Kuypers DR. Transplant Rev (Orlando). 2013 Aug 14.

[Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission.](#)

Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibañez M. Intensive Care Med. 2013 Aug 16.

[HIV-1 Infected Lymphoid Organs Upregulate Expression and Release of the Cleaved Form of uPAR That Modulates Chemotaxis and Virus Expression.](#)

Nebuloni M, Zawada L, Ferri A, Tosoni A, Zerbi P, Resnati M, Poli G, Genovese L, Alfano M.

PLoS One. 2013 Jul 29;8(7):e70606.

[Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.](#)

Enocsson H, Wetterö J, Skogh T, Sjöwall C. Transl Res. 2013 Aug 1.

[Has the circulating permeability factor in primary FSGS been found?](#)

Ashley Jefferson J, Shankland SJ. Kidney Int. 2013 Aug;84(2):235-8.

[Is There Clinical Value in Measuring suPAR Levels in FSGS?](#)

Sever S, Trachtman H, Wei C, Reiser J. Clin J Am Soc Nephrol. 2013 Jul 25.

[Circulating Permeability Factor suPAR: From Concept to Discovery to Clinic.](#)

Reiser J. Trans Am Clin Climatol Assoc. 2013;124:133-8.

[suPAR and FSGS: The Gap Between Bench and Bedside.](#)

Naesens M, Meijers B, Sprangers B. Transplantation. 2013 Jul 11.

[Soluble Urokinase Plasminogen Activator Receptor for Risk Prediction in Patients Admitted with Acute Chest Pain.](#)

Lyngbæk S, Andersson C, Marott JL, Møller DV, Christiansen M, Iversen KK, Clemmensen P, Eugen-Olsen J, Hansen PR, Jeppesen JL. Clin Chem. 2013 Jul 10. – suPARnostic®

[Podocyte Effacement Closely Links to suPAR Levels at Time of Posttransplantation Focal Segmental Glomerulosclerosis Occurrence and Improves With Therapy.](#)

Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM. Transplantation. 2013 Jul 9.

[Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infections.](#)

Dupuy AM, Philippart F, Péan Y, Lasocki S, Charles PE, Chalumeau M, Claessens YE, Quenot JP, Guen CG, Ruiz S, Luyt CE, Roche N, Stahl JP, Bedos JP, Pugin J, Gauzit R, Misset B, Brun-Buisson C; Maurice Rapin Institute Biomarkers Group. Ann Intensive Care. 2013 Jul 9;3(1):22.

[Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children.](#)

Wrotek A, Pawlik K, Jackowska T. Adv Exp Med Biol. 2013;788:329-34.

[Transplantation: Urine-but not serum-suPAR might predict FSGS recurrence.](#)

Kelsey R. Nat Rev Nephrol. 2013 Aug;9(8):432.

[No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.](#)

Mortensen C, Karlsen S, Grønbaek H, Nielsen DT, Frevert S, Clemmesen JO, Møller S, Jensen JS, Bendtsen F. Liver Int. 2013 May 9. – suPARnostic®

[Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.](#)

Asciutto G, Edsfeldt A, Dias NV, Nilsson J, Prehn C, Adamski J, Gonçalves I. Cardiovasc Pathol. 2013 Jun 5.

[The significance of serum urokinase plasminogen activation receptor \(suPAR\) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.](#)

Kaya S, Köksal I, Menteşe A, Sönmez M, Sümer A, Yıldırım SS, Yılmaz G.  
Int J Infect Dis. 2013 Jun 3. – [\*\*suPARnostic\*\*](#)<sup>®</sup>

[Urine But Not Serum Soluble Urokinase Receptor \(suPAR\) May Identify Cases of Recurrent FSGS in Kidney Transplant Candidates.](#)

Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H. Transplantation. 2013 Jun 3.

[Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high sensitivity c-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic hemodialysis patients?](#)

Almroth G, Lönn J, Uhlin F, Nayeri F, Brudin L, Andersson B, Hahn-Zoric M.  
Scand J Immunol. 2013 May 31. – [\*\*suPARnostic\*\*](#)<sup>®</sup>

[Serum Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Idiopathic FSGS in Children: A Single-Center Report.](#)

Bock ME, Price HE, Gallon L, Langman CB. Clin J Am Soc Nephrol. 2013 Apr 25.

[The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor \(suPAR\) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status.](#)

Heraclides A, Jensen TM, Rasmussen SS, Eugen-Olsen J, Haugaard SB, Borch-Johnsen K, Sandbæk A, Lauritzen T, Witte DR. Diabetologia. 2013 Apr 24. – [\*\*suPARnostic\*\*](#)<sup>®</sup>

[Circulating factor in FSGS: a black sheep in the suPAR family?](#)

Trachtman H, Wei C, Reiser J. Pediatr Nephrol. 2013 Apr 10.

[Relationship of circulating soluble urokinase plasminogen activator receptor \(suPAR\) levels to disease control in asthma and asthmatic pregnancy.](#)

Ivancsó I, Toldi G, Bohács A, Eszes N, Müller V, Rigó J Jr, Vásárhelyi B, Losonczy G, Tamási L.  
PLoS One. 2013;8(4):e60697. – [\*\*suPARnostic\*\*](#)<sup>®</sup>

[Soluble urokinase plasminogen activator receptor, C-reactive protein and triglyceride are associated with heart rate variability in non-diabetic Danes.](#)

Intzilakis T, Hartmann G, Mouridsen MR, Eugen-Olsen J, Kumarathurai P, Madsbad S, Almdal TP, Haugaard SB, Sajadieh A. Eur J Clin Invest. 2013 May;43(5):457-68. – [\*\*suPARnostic\*\*](#)<sup>®</sup>

[NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study.](#)

Kruger R, Schutte R, Huisman HW, Hindersson P, Olsen MH, Eugen-Olsen J, Schutte AE.  
PLoS One. 2013;8(3):e58506. – [\*\*suPARnostic\*\*](#)<sup>®</sup>

[Serum suPAR in patients with FSGS: trash or treasure?](#)

Maas RJ, Deegens JK, Wetzels JF. Pediatr Nephrol. 2013 Mar 21. – [\*\*suPARnostic\*\*](#)<sup>®</sup>

[Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer.](#)

Fidan E, Mentese A, Ozdemir F, Deger O, Kavgaci H, Caner Karahan S, Aydin F.

Med Oncol. 2013 Jun;30(2):540. – [suPARnostic®](#)

[Effects of acute exercise and allopurinol administration on soluble urokinase plasminogen activator receptor \(suPAR\).](#)

Sanchis-Gomar F, Bonaguri C, Pareja-Galeano H, Gomez-Cabrera MC, Candel J, Viña J, Lippi G. Clin Lab. 2013;59(1-2):207-10. – [suPARnostic®](#)

[Inflammatory Markers in the Second Trimester Prior to Clinical Onset of Preeclampsia, Intrauterine Growth Restriction, and Spontaneous Preterm Birth.](#)

Haedersdal S, Salvig JD, Aabye M, Thorball CW, Ruhwald M, Ladelund S, Eugen-Olsen J, Secher NJ. Inflammation. 2013 Mar 8. – [suPARnostic®](#)

[Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.](#)

Morath C, Wei C, Macher-Goeppinger S, Schwenger V, Zeier M, Reiser J. Am J Ther. 2013 Mar;20(2):226-9.

[Soluble urokinase plasminogen activator receptor \(suPAR\) is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.](#)

Zimmermann HW, Reuken PA, Koch A, Bartneck M, Adams DH, Trautwein C, Stallmach A, Tacke F, Bruns T. J Intern Med. 2013 Feb 21. – [suPARnostic®](#)

[Glomerular disease: 'suPAR'-exciting times for FSGS.](#)

Jefferson JA, Alpers CE. Nat Rev Nephrol. 2013 Mar;9(3):127-8.

## 2012

[Soluble urokinase plasminogen activator receptor levels in tuberculosis patients at high risk for multidrug resistance.](#)

Mardining Raras TY, Astuti T, Noor Chozin I. Tuberc Res Treat. 2012;2012:240132. – [suPARnostic®](#)

[Transmission of Glomerular Permeability Factor Soluble Urokinase Plasminogen Activator Receptor \(suPAR\) From a Mother to Child.](#)

Kemper MJ, Wei C, Reiser J. Am J Kidney Dis. 2012 Nov 19.

[The importance of biomarkers in neonatology.](#)

Mussap M, Noto A, Cibecchini F, Fanos V.

Semin Fetal Neonatal Med. 2012 Nov 16. – [suPARnostic®](#)

[Diagnostic accuracy of soluble urokinase plasminogen activator receptor \(suPAR\) for prediction of bacteremia in patients with systemic inflammatory response syndrome.](#)

Hoenigl M, Raggam RB, Wagner J, Valentin T, Leitner E, Seeber K, Zollner-Schwetz I, Krammer W, Prüller F, Grisold AJ, Krause R. Clin Biochem. 2012 Nov 13. – [suPARnostic®](#)

[Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study.](#)

Oliveira I, Andersen A, Furtado A, Medina C, da Silva D, da Silva ZJ, Aaby P, Laursen AL, Wejse C, Eugen-Olsen J; for the Bissau HIV cohort study group. BMJ Open. 2012 Nov 14;2(6).– [suPARnostic®](#)

[Soluble Urokinase Plasminogen Activator Receptor is Associated With Inflammation in the Vulnerable Human Atherosclerotic Plaque.](#)

Edsfeldt A, Nitulescu M, Grufman H, Grönberg C, Persson A, Nilsson M, Persson M, Björkbacka H, Gonçalves I. Stroke. 2012 Dec;43(12):3305-12. – **suPARnostic®**

[Circulating suPAR in Two Cohorts of Primary FSGS.](#)

Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J; for the PodoNet and FSGS CT Study Consortia. J Am Soc Nephrol. 2012 Dec;23(12):2051-2059.

[Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.](#)

Yeh YH, Wang PH, Lin LY, Tee YT, Chou MC, Yang SF, Tsai HT. Clin Chim Acta. 2012 Oct 29;415C:138-144.

[SuPAR and PAI-1 in critically ill, mechanically ventilated patients.](#)

Jalkanen V, Yang R, Linko R, Huhtala H, Okkonen M, Varpula T, Pettilä V, Tenhunen J; The FINNALI Study Group. Intensive Care Med. 2012 Oct 26. – **suPARnostic®**

[Transmission of Angiosarcomas From a Common Multiorgan Donor to Four Transplant Recipients.](#)

Thoning J, Liu Y, Bistrup C, Thomassen A, Borst C, Marcussen N, Tepel M. Am J Transplant. 2012 Oct 24.

[Plasma soluble urokinase plasminogen activator receptor \(suPAR\) levels in ankylosing spondylitis.](#)

Toldi G, Szalay B, Bekő G, Kovács L, Vásárhelyi B, Balog A. Joint Bone Spine. 2012 Sep 19. – **suPARnostic®**

[Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.](#)

Lyngbæk S, Marott JL, Møller DV, Christiansen M, Iversen KK, Clemmensen PM, Eugen-Olsen J, Jeppesen JL, Hansen PR. Am J Cardiol. 2012 Sep 12. – **suPARnostic®**

[Are Plasma Biomarkers of Immune Activation Predictive of HIV Progression: A Longitudinal Comparison and Analyses in HIV-1 and HIV-2 Infections?](#)

Nyamweya S, Townend J, Zaman A, Steele SJ, Jeffries D, Rowland-Jones S, Whittle H, Flanagan KL, Jaye A. PLoS One. 2012;7(9):e44411. – **suPARnostic®**

[\[Can Mannose-Binding Lectin and Plasma Level of Soluble Urokinase Receptor be Used in Diagnosis and Treatment Monitorization of Brucellosis Patients?\]](#)

Karsen H, Cesur S, Karaağaç L, Binici I, Fidan Y, Oğuş E, Demiröz AP. Mikrobiyol Bul. 2012 Jul;46(3):519-21. Turkish.

[Utility of the Plasma Level of suPAR in Monitoring Risk of Mortality during TB Treatment.](#)

Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Haaland MB, Aaby P, Eugen-Olsen J. PLoS One. 2012;7(8):e43933. – **suPARnostic®**



[Cardiovascular risk prediction in the general population with use of \*\*suPAR\*\*, CRP, and Framingham Risk Score.](#)

Lyngbæk S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, Linneberg A, Haugaard SB, Eugen-Olsen J, Hansen PR, Jeppesen J. *Int J Cardiol.* 2012 Aug 18. – **suPARnostic**<sup>®</sup>

[Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor.](#)

Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I, Dimopoulou I, Mouktaroudi M, Raftogiannis M, Georgitsi M, Linner A, Adamis G, Antonopoulou A, Apostolidou E, Chrisofos M, Katsenos C, Koutelidakis I, Kotzampassi K, Koratzanis G, Koupetori M, Kritselis I, Lymberopoulou K, Mandragos K, Marioli A, Sunden-Cullberg J, Mega A, Prekates A, Routsis C, Gogos C, Treutiger CJ, Armaganidis A, Dimopoulos G. *Crit Care.* 2012 Aug 8;16(4):R149. – **suPARnostic**<sup>®</sup>

[Regarding Maas's editorial letter on serum \*\*suPAR\*\* levels.](#)

Trachtman H, Gipson DS, Kaskel F, Ghiggeri GM, Faul C, Gupta V, Fornoni A, Burke GW 3rd, Thomas DB, Barisoni L, Schaefer F, Wei C, Reiser J. *Kidney Int.* 2012 Aug;82(4):492.

[Plasma \*\*suPAR\*\* levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study.](#)

Haupt TH, Petersen J, Ellekilde G, Klausen HH, Thorball CW, Eugen-Olsen J, Andersen O. *Crit Care.* 2012 Jul 23;16(4):R130. – **suPARnostic**<sup>®</sup>

[Serum soluble urokinase plasminogen activator receptor \(\*\*suPAR\*\*\) in early pregnancy prior to clinical onset of preeclampsia.](#)

Odden N, Henriksen T, Mørkrid L. *Acta Obstet Gynecol Scand.* 2012 Oct;91(10):1226-32. – **suPARnostic**<sup>®</sup>

[Risk stratification and triage in the emergency department: has this become 'suPAR' easy?](#)

Koch A, Tacke F. *J Intern Med.* 2012 Jul 3. – **suPARnostic**<sup>®</sup>

[Soluble urokinase-type plasminogen activator receptor \(\*\*suPAR\*\*\) in patients with suspected infection in the emergency room: a prospective cohort study.](#)

Uusitalo-Seppälä R, Huttunen R, Tarkka M, Aittoniemi J, Koskinen P, Leino A, Vahlberg T, Rintala EM. *J Intern Med.* 2012 Jul 3. – **suPARnostic**<sup>®</sup>

[Soluble urokinase plasminogen activator receptor \*\*suPAR\*\* as a marker for inflammation in pediatric inflammatory bowel disease.](#)

Kolho KL, Valtonen E, Rintamäki H, Savilahti E. *Scand J Gastroenterol.* 2012 Jul 2. – **suPARnostic**<sup>®</sup>

[Soluble urokinase plasminogen activator receptor \(\*\*suPAR\*\*\) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission.](#)

Toldi G, Bekó G, Kádár G, Mácsai E, Kovács L, Vászárhelyi B, Balog A. *Clin Chem Lab Med.* 2012 Jun 21;0(0):1-6. – **suPARnostic**<sup>®</sup>

[Usefulness of \*\*suPAR\*\* as a biological marker in patients with systemic inflammation or infection: a systematic review.](#)

Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, Schultz MJ. *Intensive Care Med.* 2012 Jun 16. – **suPARnostic**<sup>®</sup>

[Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?](#)

Pawlak K, Ulazka B, Mysliwiec M, Pawlak D. Transl Res. 2012 May 8.

[Targeting signaling pathways in glomerular diseases.](#)

Henique C, Tharaux PL. Curr Opin Nephrol Hypertens. 2012 Jul;21(4):417-27.

[Soluble urokinase plasminogen activator receptor in patients with abdominal aortic aneurysm.](#)

Lindqvist M, Wallinder J, Henriksson AE. Thromb Res. 2012 May 25.

[Immunoregulatory protein profiles of necrotizing enterocolitis versus spontaneous intestinal perforation in preterm infants.](#)

Chan KY, Leung FW, Lam HS, Tam YH, To KF, Cheung HM, Leung KT, Poon TC, Lee KH, Li K, Fok TF, Ng PC. PLoS One. 2012;7(5):e36977.

[Soluble urokinase receptor and focal segmental glomerulosclerosis.](#)

Reiser J, Wei C, Tumlin J. Curr Opin Nephrol Hypertens. 2012 Jul;21(4):428-32.

[The Prognostic Value of suPAR Compared to Other Inflammatory Markers in Patients with Severe Sepsis.](#)

Gustafsson A, Ljunggren L, Bodelsson M, Berkestedt I. Biomark Insights. 2012;7:39-44. – suPARnostic®

[CRP and suPAR are differently related to anthropometry and subclinical organ damage.](#)

Lyngbæk S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, Linneberg A, Madsbad S, Haugaard SB, Eugen-Olsen J, Jeppesen J. Int J Cardiol. 2012 Mar 27. – suPARnostic®

[\[A circulating factor responsible for FSGS? suPAR!\].](#)

Esposito V. G Ital Nefrol. 2012 Jan-Feb;29(1):7. Italian..

[HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients.](#)

Kasang C, Ulmer A, Donhauser N, Schmidt B, Stich A, Klinker H, Kalluvya S, Koutsilieri E, Rethwilm A, Scheller C. BMC Infect Dis. 2012 Jan 20;12:14. – suPARnostic®

[suPAR as a prognostic biomarker in sepsis.](#)

Donadello K, Scolletta S, Covajes C, Vincent JL. BMC Med. 2012 Jan 5;10:2. Review. – suPARnostic®

[The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.](#)

Haugaard SB, Andersen O, Hansen TW, Eugen-Olsen J, Linneberg A, Madsbad S, Olsen MH, Jørgensen T, Borch-Johnsen K, Jeppesen J. Diabet Med. 2012 Apr;29(4):479-487. - suPARnostic®

[Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.](#)

Persson M, Engström G, Björkbacka H, Hedblad B. Atherosclerosis. 2012 Feb;220(2):502-5. - suPARnostic®

[Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.](#)

Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Liver Int. 2012 Mar;32(3):500-9. – suPARnostic®

[Elevated urinary levels of urokinase-type plasminogen activator receptor \(uPAR\) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.](#)

Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G, Blasi F, Talamini G, Bassi C, Scarpa A. BMC Cancer. 2011 Oct 14;11:448.

[Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.](#)

Tzanakaki G, Paparoupa M, Kyprianou M, Barbouni A, Eugen-Olsen J, Kourea-Kremastinou J. Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1157-62. - suPARnostic®

[suPAR as a prognostic biomarker in sepsis.](#)

Donadello K, Scolletta S, Covajes C, Vincent JL. BMC Med. 2012 Jan 5;10:2. - suPARnostic®

## 2011

[Why high suPAR is not super - diagnostic, prognostic and potential pathogenic properties of a novel biomarker in the ICU. \(Commentary\)](#)

Koch A, Tacke F. Crit Care. 2011 Dec 15;15(6):1020. - suPARnostic®

[Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study.](#)

Schutte AE, Myburgh A, Olsen MH, Eugen-Olsen J, Schutte R. Thromb Res. 2011 Nov 21. - suPARnostic®

[Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study.](#)

Backes Y, van der Sluijs KF, Tuip de Boer AM, Hofstra JJ, Vlaar AP, Determann RM, Knappe P, Mackie DP, Schultz MJ. Crit Care. 2011 Nov 16;15(6):R270 - suPARnostic®

[Soluble urokinase plasminogen activator receptor \(suPAR\) levels in healthy pregnancy and preeclampsia.](#)

Toldi G, Bíró E, Szalay B, Stenczer B, Molvarec A, Rigó J, Vásárhelyi B, Bekő G. Clin Chem Lab Med. 2011 Nov;49(11):1873-6. - suPARnostic®

[The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome](#)

Yilmaz G, Köksal I, Karahan SC, Mentese A. Clin Biochem. 2011 Oct;44(14-15):1227-30. - suPARnostic®

[Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.](#)

Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Liver Int. 2011 Oct 17. - suPARnostic®

[Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.](#)

Tzanakaki G, Paparoupa M, Kyprianou M, Barbouni A, Eugen-Olsen J, Kourea-Kremastinou J. Eur J Clin Microbiol Infect Dis. 2011 Oct 5. - suPARnostic®

[Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection.](#)

Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE. J Clin Gastroenterol. 2011 Sep 19. - suPARnostic®

[A suPAR circulating factor causes kidney disease](#)

Shankland SJ, Pollak MR. Nat Med. 2011 Aug 4;17(8):926-7.

[Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.](#)

Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J.

Nat Med. 2011 Jul 31;17(8):952-60.

[Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels.](#)

Gustafsson A, Ajeti V, Ljunggren L. Biomark Insights. 2011;6:119-25. - suPARnostic®

[Elevated soluble urokinase plasminogen activator receptor \(suPAR\) predicts mortality in Staphylococcus aureus bacteremia.](#)

Mölkänen T, Ruotsalainen E, Thorball CW, Järvinen A.

Eur J Clin Microbiol Infect Dis. 2011 Apr 12. – suPARnostic®

[Soluble Urokinase Plasminogen Activator Receptor \(suPAR\) is Associated with Metabolic Changes in HIV-1-Infected Africans: A Prospective Study.](#)

Fourie CM, Van Rooyen JM, Kruger A, Olsen MH, Eugen-Olsen J, Schutte R, Schutte AE.

Inflammation. 2011 Mar 8. – suPARnostic®

[suPAR - a future risk marker.](#)

Eugen-Olsen J. J Intern Med. 2011 Mar 3. – suPARnostic®

[Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study](#)

Huttunen R, Syrjänen R, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J.

Journal of Internal Medicine. 2011 Feb.– suPARnostic®

[Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Organ Damage And Cardiovascular Events](#)

T. Sehestedt, S. Lyngbæk, J. Eugen-Olsen, J. Jeppesen, O. Andersen, T.W. Hansen, A. Linneberg, T.

Jørgensen, S.B. Haugaard and M.H. Olsen. Science Direct. 2011 Feb 22. – suPARnostic®

[Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.](#)

Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke

F. Crit Care. 2011 Feb 16;15(1):R63.– suPARnostic®

[Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1.](#)

Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, Weis N.

Eur J Clin Microbiol Infect Dis. 2011 Jan 13. – suPARnostic®

[Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals.](#)

Langkilde AA, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, Jeppesen J, Eugen-Olsen J. Cancer Epidemiol Biomarkers Prev. 2011 Jan 14. – suPARnostic®

## 2010

[Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation.](#)

Haastrup E, Andersen J, Ostrowski SR, Høyer-Hansen G, Jacobsen N, Heilmann C, Ullum H, Müller K. Scand J Immunol. 2011 Jan 11.

[The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever.](#)

Yilmaz G, Mentese A, Kaya S, Uzun A, Karahan SC, Koksal I. J Clin Virol. 2010 Dec 15. – suPARnostic®

[Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy.](#)

Lönnkvist MH, Theodorsson E, Holst M, Ljung T, Hellström PM. Scand J Gastroenterol. 2010 Nov 30. – suPARnostic®

[Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.](#)

Kjellman A, Akre O, Gustafsson O, Høyer-Hansen G, Lilja H, Norming U, Piironen T, Törnblom M. J Intern Med. 2010 Sep 1.

[Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.](#)

Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB. J Intern Med. 2010 Sep;268(3):296-308. – suPARnostic®

[Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study.](#)

Rabna P, Andersen A, Wejse C, Oliveira I, Francisco Gomes V, Bonde Haaland M, Aaby P, Eugen-Olsen J. Inflammation. 2010 Dec;33(6):374-80. – suPARnostic®

[Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.](#)

Pawlak K, Buraczewska-Buczko A, Mysliwiec M, Pawlak D. Am J Med Sci. 2010 Jan;339(1):5-9.

## 2009

[suPAR: the molecular crystal ball.](#)

Thunø M, Macho B, Eugen-Olsen J. Dis Markers. 2009;27(3):157-72. Review.

[Release of the soluble urokinase-type plasminogen activator receptor \(suPAR\) by activated neutrophils in rheumatoid arthritis.](#)

Pliyev BK, Menshikov MY. Inflammation. 2010 Feb;33(1):1-9.

[High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test.](#)

Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Haaland MB, Aaby P, Eugen-Olsen J.

Trop Med Int Health. 2009 Sep;14(9):986-94. – suPARnostic®

[Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency.](#)

Fevang B, Eugen-Olsen J, Yndestad A, Brosstad F, Beiske K, Aukrust P, Frøland SS.

Clin Immunol. 2009 Jun;131(3):438-46. – suPARnostic®